Citations

Clear

1893 citation(s) found for "Wu, Kenneth".

Estimating head and neck tissue dose from x-ray scatter to physicians performing x-ray guided cardiovascular procedures: a phantom study
Fetterly, Kenneth A. , Schueler, Beth A. , Sturchio, Glenn M., Grams, Michael P.

Mayo Clinic

Journal of Radiological Protection | December 12, 2016 | Volume: 37 | Issue: 1 | Pages: 43-58

10.1088/1361-6498/37/1/43 | PMID 27941226 Get It

Abstract Physicians performing x-ray guided interventional procedures have a keen interest in radiation safety. Radiation dose to tissues and organs of the head and neck are of particular interest because they are not routinely protected by wearable radiation safety devices. This study was conducted to facilitate estimation of radiation dose to tissues of the head and neck of interventional physicians based on the dose recorded by a personal dosimeter worn on the left collar. Scatter beam qualities maximum energy and HVL were measured for 40 scatter beams emitting from an anthropomorphic patient phantom. Variables of the scatter beams included scatter angle (35° and 90°), primary beam peak tube potential (60, 80, 100, and 120 kVp), and 5 Cu spectral filter thicknesses (0–0.9 mm). Four reference scatter beam qualities were selected to represent the range of scatter beams realized in a typical practice. A general radiographic x-ray tube was tuned to produce scatter-equivalent radiographic beams and used to simultaneously expose the head and neck of an anthropomorphic operator phantom and radiochromic film. The geometric relationship between the x-ray source of the scatter-equivalent beams and the operator phantom was set to mimic that between a patient and physician performing an invasive cardiovascular procedure. Dose to the exterior surface of the operator phantom was measured with both 3 × 3 cm 2 pieces of film and personal dosimeters positioned at the location of the left collar. All films were scanned with a calibrated flatbed scanner, which converted the film’s reflective density to dose. Films from the transverse planes of the operator phantom provided 2D maps of the dose distribution within the phantom. These dose maps were normalized by the dose at the left collar, providing 2D percent of left collar dose (LCD) maps. The percent LCD maps were overlain with bony anatomy CT images of the operator phantom and estimates of percent LCD to the left, right and whole brain, brain stem, lenses of the eyes, and carotid arteries were calculated. Per expectation, results indicated greater percent dose to superficial versus deep tissues and increasing percent dose to deep tissues with increasing scatter-equivalent beam energy and HVL. The results enable estimation of the scatter dose to tissues of the head and neck of interventional physicians based on occupational dose measured by a personal dosimeter worn at the collar outside the protective apron.
Balloon Valvuloplasty to Predict X‐ray Projection Angles that are Perpendicular to Cardiovascular Structures
Fetterly, Kenneth A. , Greason, Kevin L. , Mathew, Verghese, Fetterly, Kenneth, Greason, Kevin

Mayo Clinic

Catheterization and Cardiovascular Interventions | November 29, 2016 | Volume: 90 | Issue: 3 | Pages: 480-485

10.1002/ccd.26879 | PMID 27896912 Get It

ObjectivesThe purpose of this work is to describe methods to measure the 3D angular orientation of cardiovascular structures based on a planar image of a valvuloplasty balloon. These methods facilitate X‐ray beam alignment with respect to the anatomy of interest.BackgroundX‐ray beam projections which are perpendicular to the long axis of cardiovascular structures are required to support interventional procedures, including transcatheter aortic valve implant (TAVI).MethodsDuring the TAVI procedure, the 3D angular orientation of the LVOT of 10 patients was measured from a single planar image of an aortic valvuloplasty balloon and the continuous range of X‐ray projection angles which are aligned with the aortic valve plane were calculated (research method). Misalignment of the X‐ray beam and TAVI valve frame was measured from images of the deployed valve. The accuracy of the research method was compared to clinical standard method to determine appropriate X‐ray projection angles, which utilized CT and aortography.ResultsUsing the clinical standard method, the median misalignment of the X‐ray beam and TAVI valve frame was 8.6° (range 2.6° to 21°). Misalignment was reduced to 2.5° (range 0° to 10°) using the research method.ConclusionsThe 3D angular orientation of cardiovascular structures can be measured accurately from a single X‐ray projection image of a known cardiovascular device contained within the anatomy of interest. For TAVI procedures, improved X‐ray beam alignment may help facilitate procedural success. © 2016 Wiley Periodicals, Inc.
Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers
Kuchenbaecker, Karoline , McGuffog, Lesley , Barrowdale, Daniel , Lee, Andrew , Soucy, Penny, Ramus, Susan J. , Terry, Mary Beth , Schmutzler, Rita K., Simard, Jacques , Pharoah, Paul D.P., Offit, Kenneth, Chenevix‐Trench, Georgia , Easton, Douglas F. , Antoniou, Antonis C, Nathanson, Katherine L. , Radice, Paolo , Jakubowska, Anna , Lubiński, Jan , Engel, Christoph , Durocher, Francine , Weitzel, Jeffrey N. , Olopade, Olufunmilayo I. , John, Esther M. , Southey, Melissa C. , Eeles, Rosalind A. , Benı́tez, Javier , Ganz, Patricia A. , Gómez, E. , Peterlongo, Paolo , Pensotti, Valeria , Giannini, Giuseppe , Jensen, Uffe Birk , Caligo, Maria A. , Ehrencrona, Hans , Adlard, Julian , Eccles, Diana , Mazoyer, Sylvie , Montagna, Marco , Teo, Soo‐Hwang , Rensburg, Elizabeth J. van , Dı́ez, Orland , Hoya, Miguel de la , Mulligan, Anna Marie , Konstantopoulou, Irene , Vijai, Joseph , Brunet, Joan , Kwong, Ava , James, Paul A. , Claes, Kathleen , Doorn, Helena C. van , Teixeira, Manuel R. , Rennert, Gad , Hulick, Peter J. , Lesueur, Fabienne , Azzollini, Jacopo , Hauke, Jan , Teulé, Àlex , Dennis, Joe , Domchek, Susan M. , Robson, Mark E. , Spurdle, Amanda B. , Mavaddat, Nasim , Neuhausen, Susan L. , Couch, Fergus J. , Antoniou, Antonis C. , Caligo, Maria A , Hulick, Peter J , James, Paul , Lesueur, Fabienne , Peterlongo, Paolo , Ramus, Susan J , Rennert, Gad , Teixeira, Manuel R , Teo, Soo H , van Rensburg, Elizabeth J , Eccles, Diana , de la Hoya, Miguel , Diez, Orland , Radice, Paolo , Weitzel, Jeffrey N , Claes, Kathleen B M , Adlard, Julian , Azzollini, Jacopo , Brunet, Joan , Eeles, Rosalind A , Ehrencrona, Hans , John, Esther M , Joseph, Vijai , Konstantopoulou, Irene , Olopade, Olufunmilayo I , Southey, Melissa C , Jakubowska, Anna , Nathanson, Katherine L , Barrowdale, Daniel , Benitez, Javier , Engel, Christoph , Montagna, Marco , Simard, Jacques , Chenevix-Trench, Georgia , Gómez-García, Encarna B , Hauke, Jan , Lubinski, Jan , Terry, Mary Beth , Kwong, Ava

Mayo Clinic

JNCI: Journal of the National Cancer Institute | November 29, 2016 | Volume: 109 | Issue: 7 | Pages: No page available

10.1093/jnci/djw302 | PMID 28376175 Get It

SNP interaction pattern identifier (SIPI): an intensive search for SNP–SNP interaction patterns
Lin, Hui‐Yi , Chen, Dung‐Tsa, Huang, Po-Yu, Liu, Yung-Hsin, Zabaleta, Jovanny , Mercante, Donald E., Fang, Zhide , Sellers, Thomas A. , Pow‐Sang, Julio M. , Cheng, Chia‐Ho, Eeles, Rosalind A. , Easton, Doug , Olama, Ali Amin Al , Benlloch, Sara, Muir, Kenneth , Grönberg, Henrik , Haiman, Christopher A. , Schleutker, Johanna , Nordestgaard, Børge G. , Travis, Ruth C. , Hamdy, Freddie C. , Pashayan, Nora , Stanford, Janet L. , Blot, William J. , Thibodeau, Stephen N. , Maier, Christiane, Kibel, Adam S. , Brenner, Hermann , Kaneva, Radka , Batra, Jyotsna , Teixeira, Manuel R. , Pandha, Hardev, Lu, Yong‐Jie , Ochoa, Augusto C. , Kote‐Jarai, Zsofia , Giles, Graham G. , Wiklund, Fredrik E. , Khaw, Kay‐Tee , Cybulski, Cezary , Cannon‐Albright, Lisa , Park, Jong Y. , Teixeira, Manuel R , Eeles, Rosalind A , Muir, Kenneth , Schleutker, Johanna , Travis, Ruth C , Pashayan, Nora , Lin, Hui-Yi , Brenner, Hermann , Batra, Jyotsna , Zabaleta, Jovanny

Mayo Clinic

Bioinformatics | November 29, 2016 | Volume: 33 | Issue: 6 | Pages: 822-833

10.1093/bioinformatics/btw762 | PMID 28039167 Get It

Abstract Motivation Testing SNP–SNP interactions is considered as a key for overcoming bottlenecks of genetic association studies. However, related statistical methods for testing SNP–SNP interactions are underdeveloped. Results We propose the SNP Interaction Pattern Identifier (SIPI), which tests 45 biologically meaningful interaction patterns for a binary outcome. SIPI takes non-hierarchical models, inheritance modes and mode coding direction into consideration. The simulation results show that SIPI has higher power than MDR (Multifactor Dimensionality Reduction), AA_Full, Geno_Full (full interaction model with additive or genotypic mode) and SNPassoc in detecting interactions. Applying SIPI to the prostate cancer PRACTICAL consortium data with approximately 21 000 patients, the four SNP pairs in EGFR-EGFR, EGFR-MMP16 and EGFR-CSF1 were found to be associated with prostate cancer aggressiveness with the exact or similar pattern in the discovery and validation sets. A similar match for external validation of SNP–SNP interaction studies is suggested. We demonstrated that SIPI not only searches for more meaningful interaction patterns but can also overcome the unstable nature of interaction patterns. Availability and Implementation The SIPI software is freely available at http://publichealth.lsuhsc.edu/LinSoftware/. Supplementary information Supplementary data are available at Bioinformatics online.
Funding Research in Emergency Department Shared Decision Making: A Summary of the 2016 Academic Emergency Medicine Consensus Conference Panel Discussion
Dodd, Kenneth W. , Berman, Amy , Carr, Brendan G. , Dunn, Patrick , Escobedo, Marcus, Gayer, Christopher, Grieser, Mira, Carpenter, Christopher R. , Grudzen, Corita R. , Brown, Jeremy , Hess, Erik P. , Carpenter, Christopher R

Mayo Clinic

Academic Emergency Medicine | November 28, 2016 | Volume: 23 | Issue: 12 | Pages: 1340-1345

10.1111/acem.13063 | PMID 27474887 Get It

AbstractAs part of the 2016 Academic Emergency Medicine Consensus Conference, “Shared Decision Making in the Emergency Department: Development of a Policy‐relevant Patient‐centered Research Agenda,” a panel of representatives from the Office of Emergency Care Research, the Patient‐Centered Outcomes Research Institute, the American Heart Association, the John A. Hartford Foundation, and the Emergency Care Coordination Center were assembled to discuss funding opportunities for future research in this field. This article summarizes their discussion of funding priorities and examples of successfully funded projects related to shared decision making in emergency medicine.
Immune Therapies in Multiple Myeloma
Kumar, Shaji , Anderson, Kenneth C.

Mayo Clinic

Clinical Cancer Research | November 15, 2016 | Volume: 22 | Issue: 22 | Pages: 5453-5460

10.1158/1078-0432.ccr-16-0868 | PMID 28151713 Get It

Abstract Treatment paradigms have changed rapidly for multiple myeloma, and immune therapies have taken center stage. Advances in therapies for myeloma have led to a dramatic improvement in the survival of patients with this incurable malignancy. The immune system is significantly impaired in patients with myeloma as a result of the disease leading to suppression of normal plasma cells as well the negative effects on cellular immunity. Given this scenario, immune approaches have not been successful until recently. Monoclonal antibodies directed against CD38 (daratumumab) and SLAMF7 (elotuzumab) are already in the clinic, and several other antibodies directed against different plasma cell antigens are under evaluation. Although immune checkpoint inhibition with PD-1 inhibitors had no clinical efficacy when the inhibitors were used as single agents, it has led to some dramatic results when the inhibitors are combined with immunomodulatory drugs such as lenalidomide and pomalidomide. Vaccination strategies have shown in vivo immune responses but no clear clinical efficacy. Newer approaches to vaccination with multiple antigens, used in combinations with immunomodulatory drugs and in the setting of minimal residual disease, have all increased possibility of this approach succeeding. Ex vivo effector cell expansion also appears to be promising and is in clinical trials. Finally, a chimeric antigen receptor T-cell approach appears to have some promise based on isolated reports of success and remains an area of intense investigation. Immune-based approaches can potentially augment or even supplant some of the current approaches and, given the low toxicity profile, may hold great potential in the early treatment of precursor-stage diseases. Clin Cancer Res; 22(22); 5453–60. ©2016 AACR. See all articles in this CCR Focus section, “Multiple Myeloma: Multiplying Therapies.”
A phase IIa study of afuresertib, an oral pan‐AKT inhibitor, in patients with Langerhans cell histiocytosis
Arceci, R.J., Allen, Carl E. , Jacobsen, Eric D. , Whitlock, James A. , Vassallo, Robert , Morris, Shannon R., Portnoy, Alison, Reedy, Beth Ann, Smith, Deborah A. , Noble, Robert, Murnane, Amy A., Cornfeld, Mark, Heaney, Mark , McClain, Kenneth L. , Vaiselbuh, Sarah R., Dunkel, Ira J. , Rodríguez‐Galindo, Carlos , Vassallo, Robert , McClain, Kenneth L , Allen, Carl E

Mayo Clinic

Pediatric Blood & Cancer | November 2, 2016 | Volume: 64 | Issue: 5 | Pages: No page available

10.1002/pbc.26325 | PMID 27804235 Get It

AbstractBackgroundLangerhans cell histiocytosis (LCH) is a clonal neoplasm characterized by widely varied clinical presentations, including multisystem involvement and systemic inflammatory symptoms. The AKT pathway is relevant to survival and proliferation of dendritic cells, and is also often upregulated in hematopoietic malignancies. A clinical response in an adult patient with LCH participating in the first‐in‐human trial of afuresertib prompted this prospective trial.ProcedureThe population in the current study included treatment‐naïve (n = 7) and recurrent/refractory patients with LCH (n = 10), who received oral afuresertib (125 mg). The majority of patients were treated for > 24 weeks, with four patients receiving treatment for > 48 weeks.ResultsPharmacokinetic analysis showed similar exposures in previously reported patients with other hematologic malignancies. Primary drug‐related toxicities included Grade 1/2 nausea, diarrhea, dyspepsia, and vomiting. Grade 3 toxicities included fatigue, diarrhea, and pain (one of each). Another severe adverse event involved soft tissue necrosis. The overall response rate in evaluable subjects was 33% in treatment‐naïve patients and 28% in patients with recurrent/refractory disease, which did not meet the predefined Bayesian criteria for efficacy.ConclusionAfuresertib has clinical activity in some patients with newly diagnosed and advanced LCH.
BET Inhibitors Suppress ALDH Activity by Targeting ALDH1A1 Super-Enhancer in Ovarian Cancer
Yokoyama, Yuhki , Zhu, Hengrui , Lee, Jeong Heon, Kossenkov, Andrew V. , Wu, Sherry Y. , Wickramasinghe, Jayamanna, Yin, Xiangfan, Palozola, Katherine C. , Showe, Louise C. , Zaret, Kenneth S. , Liu, Qin , Speicher, David W. , Conejo-García, José R. , Bradner, James E. , Zhang, Zhiguo , Ördög, Tamás , Bitler, Benjamin G. , Lee, Jeong‐Heon , Gardini, Alessandro , Sood, Anil K. , Zhang, Rugang , Zhang, Zhiguo , Lee, Jeong-Heon

Mayo Clinic

Cancer Research | November 1, 2016 | Volume: 76 | Issue: 21 | Pages: 6320-6330

10.1158/0008-5472.can-16-0854 | PMID 27803105 Get It

Abstract The emergence of tumor cells with certain stem-like characteristics, such as high aldehyde dehydrogenase (ALDH) activity due to ALDH1A1 expression, contributes to chemotherapy resistance and tumor relapse. However, clinically applicable inhibitors of ALDH activity have not been reported. There is evidence to suggest that epigenetic regulation of stem-related genes contributes to chemotherapy efficacy. Here, we show that bromodomain and extraterminal (BET) inhibitors suppress ALDH activity by abrogating BRD4-mediated ALDH1A1 expression through a super-enhancer element and its associated enhancer RNA. The clinically applicable small-molecule BET inhibitor JQ1 suppressed the outgrowth of cisplatin-treated ovarian cancer cells both in vitro and in vivo. Combination of JQ1 and cisplatin improved the survival of ovarian cancer–bearing mice in an orthotopic model. These phenotypes correlate with inhibition of ALDH1A1 expression through a super-enhancer element and other stem-related genes in promoter regions bound by BRD4. Thus, targeting the BET protein BRD4 using clinically applicable small-molecule inhibitors, such as JQ1, is a promising strategy for targeting ALDH activity in epithelial ovarian cancer. Cancer Res; 76(21); 6320–30. ©2016 AACR.
Defibrillators
Friedman, Paul A. , Ellenbogen, Kenneth A. , Al-Khatib, Sana M, Al‐Khatib, Sana M. , Ellenbogen, Kenneth A

Mayo Clinic

Circulation | October 31, 2016 | Volume: 134 | Issue: 18 | Pages: 1390-1404

10.1161/circulationaha.116.021889 | PMID 27799257 Get It

Advances in the field of defibrillation have brought to practice different types of devices that include the transvenous implantable cardioverter-defibrillator (ICD) with or without cardiac resynchronization therapy, the subcutaneous ICD (S-ICD), and the wearable cardioverter-defibrillator. To ensure optimal use of these devices and to achieve best patient outcomes, clinicians need to understand how these devices work, learn the characteristics of patients who qualify them for one type of device versus another, and recognize the remaining gaps in knowledge surrounding these devices. The transvenous ICD has been shown in several randomized clinical trials to improve the survival of patients resuscitated from near-fatal ventricular fibrillation and those with sustained ventricular tachycardia with syncope or systolic heart failure as a result of ischemic or nonischemic cardiomyopathy despite receiving guideline-directed medical therapy. Important gaps in knowledge regarding the transvenous ICD involve the role of the ICD in patient subgroups not included, or not well represented, in clinical trials and the need to refine the selection criteria for the ICD in patients who are indicated for it. S-ICDs were recently introduced into the clinical arena as another option for many patients who have an approved indication for a transvenous ICD. The main advantage of the S-ICD is a lower risk of infection and lead-related complications; however, the S-ICD does not offer bradycardia or antitachycardia pacing. The S-ICD may be ideal for patients with limited vascular access, high infection risk, or some congenital heart diseases. However, more data are needed regarding the efficacy and effectiveness of the S-ICD in comparison to transvenous ICDs, the extent of defibrillation testing required, and the use of the S-ICD with other novel technologies, including leadless pacemakers. Cardiac resynchronization therapy-defibrillators are indicated in patients with a left ventricular ejection fraction ≤35%, QRS width ≥130 ms, and New York Heart Association class II, III, or ambulatory IV symptoms despite treatment with guideline-directed medical therapy. Multiple randomized controlled trials have shown that the cardiac resynchronization therapy-defibrillator improves survival, quality of life, and several echocardiographic measures. One main challenge related to cardiac resynchronization therapy-defibrillators is the 30% nonresponse rate. Many initiatives are underway to address this challenge including improved cardiac resynchronization therapy and imaging technologies and enhanced selection of patients and device programming.
Investigating the possible causal role of coffee consumption with prostate cancer risk and progression using Mendelian randomization analysis
Taylor, Amy E. , Martin, Richard M. , Geybels, Milan S., Stanford, Janet L. , Shui, Irene M. , Eeles, Rosalind A. , Easton, Doug , Olama, Ali Amin Al , Benlloch, Sara, Muir, Kenneth , Grönberg, Henrik , Haiman, Christopher A. , Schleutker, Johanna , Nordestgaard, Børge G. , Travis, Ruth C. , Neal, David E. , Pashayan, Nora , Blot, William J. , Thibodeau, Stephen N. , Maier, Christiane, Kibel, Adam S. , Brenner, Hermann , Park, Jong, Kaneva, Radka , Batra, Jyotsna , Teixeira, Manuel R. , Pandha, Hardev, Donovan, Jenny , Munafò, Marcus R. , Thibodeau, Stephen, Easton, Douglas F. , Kote‐Jarai, Zsofia , Giles, Graham G. , Wiklund, Fredrik E. , Khaw, Kay‐Tee , Cybulski, Cezary , Cannon‐Albright, Lisa , Teixeira, Manuel R , Eeles, Rosalind A , Donovan, Jenny L , Muir, Kenneth , Schleutker, Johanna , Travis, Ruth C , Pashayan, Nora , Brenner, Hermann , Martin, Richard M , Batra, Jyotsna

Mayo Clinic

International Journal of Cancer | October 14, 2016 | Volume: 140 | Issue: 2 | Pages: 322-328

10.1002/ijc.30462 | PMID 27741566 Get It

Coffee consumption has been shown in some studies to be associated with lower risk of prostate cancer. However, it is unclear if this association is causal or due to confounding or reverse causality. We conducted a Mendelian randomisation analysis to investigate the causal effects of coffee consumption on prostate cancer risk and progression. We used two genetic variants robustly associated with caffeine intake (rs4410790 and rs2472297) as proxies for coffee consumption in a sample of 46,687 men of European ancestry from 25 studies in the PRACTICAL consortium. Associations between genetic variants and prostate cancer case status, stage and grade were assessed by logistic regression and with all‐cause and prostate cancer‐specific mortality using Cox proportional hazards regression. There was no clear evidence that a genetic risk score combining rs4410790 and rs2472297 was associated with prostate cancer risk (OR per additional coffee increasing allele: 1.01, 95% CI: 0.98,1.03) or having high‐grade compared to low‐grade disease (OR: 1.01, 95% CI: 0.97,1.04). There was some evidence that the genetic risk score was associated with higher odds of having nonlocalised compared to localised stage disease (OR: 1.03, 95% CI: 1.01, 1.06). Amongst men with prostate cancer, there was no clear association between the genetic risk score and all‐cause mortality (HR: 1.00, 95% CI: 0.97,1.04) or prostate cancer‐specific mortality (HR: 1.03, 95% CI: 0.98,1.08). These results, which should have less bias from confounding than observational estimates, are not consistent with a substantial effect of coffee consumption on reducing prostate cancer incidence or progression.